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Abstract The advent of transgenic technology has provided
methods for the production of pharmaceuticals by the isola-
tion of these proteins from transgenic animals. The mam-
mary gland has been focused on as a bioreactor, since milk
is easily collected from lactating animals and protein pro-
duction can be expressed at very high levels, including
hormones and enzymes. We demonstrate here the expres-
sion pattern of recombinant human growth hormone (rhGH)
in transgenic rabbits carrying hGH genomic sequences driv-
en by the rat whey acidic protein (WAP) promoter. The
transgene was mapped to the q26-27 telomere region of
chromosome 7q by fluorescence in situ hybridization
(FISH). Nearly 30 % of the F1 generation demonstrated
the presence of transgene. The recombinant growth hor-
mone was detected in the milk of the transgenic rabbit
females, but not in serum, up to the level of 10 μg/ml.
Ectopic expression of the transgene in the brain, heart,
kidney, liver, and salivary gland was not observed, indicat-
ing that a short sequence of rat WAP promoter (969 bp)
contained essential sequences directing expression exclu-
sively to the mammary gland. The biological activity of
recombinant growth hormone was measured by immunore-
activity and the capability to stimulate growth of the
hormone-dependent Nb211 cell line.
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Introduction
Growth hormone (GH) is a factor controlling growth in the
vertebrates and metabolism of mammals by the stimulation of
a protein synthesis and a lipid degradation. Human GH (hGH)
is composed of a single polypeptide chain of 191 amino acids
with a molecular mass of 22 kDa. It contains two internal
disulfide bonds and a tertiary structure that includes four alpha
helices arranged in an antiparallel fashion. The genomic se-
quence of hGH encompasses 1,632, nucleotides including five
exons. The growth hormone gene cluster is assigned to chro-
mosome 17q23-q24 (Niall et al. 1971; Owerbach et al. 1980;
Xu et al. 1988; Lipiński et al. 2003).
Growth hormone deficiencies (GHD) in humans are pri-
marily due to pituitary disease, adenoma, and trauma, as
well as primary deficiencies. The clinical manifestation of
human growth hormone deficiencies in adults results in
severe cardiovascular disease, causing premature death, in-
creased fat mass, reduced muscle mass, lower cardiac out-
put, lower bone density, and increased protein lipids, leading
to a substantial decrease of life quality in affected individuals.
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In children, growth hormone deficiencies additionally result in
severe growth retardation and can be congenital (e.g., Turner’s
syndrome) or acquired due to tumors or renal insufficiencies
(Collett-Solberg 2011). Reduced bonemineral density (BMD)
had been reported in patients with isolated GHD or with
multiple pituitary hormone deficiencies (Colao et al. 1999).
The only known effective treatment of this and related con-
ditions is human growth hormone replacement therapy. In
addition, a number of other medical conditions, including
Crohn’s disease, catabolic conditions like burns, coronary
vascular disease, premature aging, idiopathic osteoporosis,
and many others, have been demonstrated to be successfully
treated by human growth hormone replacement therapy
(Ayyar 2011). The first use of growth hormone therapy for
GH deficiencywas reported in 1958 (Raben 1958). Originally,
hGH therapeutic preparations were derived from human ca-
daver pituitaries, but in the mid-1980s, such production was
linked to a risk for Creutzfeldt–Jakob disease (CJD) and was
terminated (Hintz 1995). This situation started to stimulate the
development of new strategies and revealed the market of a
recombinant human GH (rhGH) beginning in 1985 (Kemp
and Frindik 2011).
In the present study, we describe an expression of a
recombinant human growth hormone in the mammary
glands of transgenic rabbits at the transcription and the
translation levels, a stability of the transgene transmission,
and a mapping of the transgene by fluorescence in situ
hybridization (FISH). The recombinant WAP:6xHishGH
vector containing the hGH gene used in this study was
sufficient to target rhGH expression into the mammary
gland of lactating animals.
Materials and methods
Sample collection
Transgenic rabbit (No. 61) generation was as described
previously (Lipiński et al. 2003). The founder male rabbit
F0 was prepared by microinjection of a gene construct
WAP:6xHishGH encompassing rat WAP promoter, histidine
tag, thrombin recognition site, and the entire genomic se-
quence of hGH in pBSK + vector (Stratagene) into zygote
(Scheme 1). When male No. 61 reached sexual maturity, his
sperm was collected and used for the artificial insemination
of non-transgenic females. As a result of this procedure, 32
transgenic rabbits of the F1 generation were generated.
When transgenic females of the F1 generation reached sex-
ual maturity, they were inseminated with the semen of the
transgenic male to obtain homozygotes. As a result of this
procedure, 34 transgenic rabbits of the F2 generation were
generated (Table 1).
Screening of transgene and sequencing
Total DNA was extracted from tissue ear bioptats using the
guanidinium/isothiocyanate method as described by Ciulla et
al. (1988). Two pairs of polymerase chain reaction (PCR)
primers were placed on both sides of the junction between
the promoter and the hGH gene encompassing part of the
WAP promoter, 6 His tag sequence, thrombin recognition site,
and the first hGH exon sequence. For the first screening, the
primers WhGH2-F (5′-Cy5-AGTCTTCCTCCTGTGGGTC-
3′) and WhGH2-R (5′-TCTCTCTCCATCCCTCCAG-3′)
were used to amplify a 313-bp DNA fragment. In the second
PCR screening, primers WhGH1-F (5′-Cy5-GTCCCAACC-
CAACCATTC-3′) and WhGH1-R (5′-TGGCGATACTCA-
CATTCAGA-3′) were used to amplify a 524-bp DNA
fragment. Primer locations are shown in Scheme 1. PCR
was conducted in a Veriti Thermal Cycler (Applied Biosys-
tems) in 25-μl reactions containing 125 ng total genomic
DNA, 1× ReadyMix™ (Sigma Aldrich) and 0.125 μM of
each primer PCR. The PCR amplification profile consisted
of an initial denaturation at 94 °C for 5 min, followed by 30
cycles at 94 °C for 45 s, 55 °C for 45 s, 72 °C for 90 s, and a
final extension at 72 °C for 10 min. PCR products were
fractionated in 6 % polyacrylamide gel (19:1, AA:BA) under
denaturing conditions on the ALFExpress sequencer. Two μl
Scheme 1 The scheme shows the gene construct WAP:6xHishGH
encompassing rat WAP promoter (987 bp), histidine tag (6xHis),
thrombin recognition site (Thr), and the entire genomic sequence of
hGH (1,468 bp). The scheme also shows the locations of the primers
used for the screening of the transgene. The distance between primers
and codon start is shown in parentheses
436 J Appl Genetics (2012) 53:435–442
of PCR products were combined with the loading buffer and
internal markers of 113 bp and 268 bp. For the analysis of
results, Fragment Manager software (Pharmacia Biotech) was
applied.
The nucleotide sequence of the whole transgene was
performed on PCR products obtained by PCR with the
genomic DNA as a template and the universal primers
M13F (5′-CGCCAGGGTTTTCCCAGTCACGAC-3′) and
M13R (5′-TCACACAGGAAACAGCTATGAC), both
flanking the transgene region. Sequencing was conducted
with automated genetic analyzers (Applied Biosystems
Prism).
Mapping of transgene
Mapping was performed by FISH using primary cell cul-
tures of skin fibroblasts. Cells were cultured for 4 days in
37 °C in an atmosphere of 5 % CO2, DMEM, antibiotic, and
15 % fetal bovine serum (Sigma Aldrich). Metaphase plates
were obtained by the addition of 0.05 μg/ml of colcemid.
Cells were harvested with 0.1 % trypsin and 0.2 % EDTA,
and treated with hypotonic solution and then fixed with a
mixture of absolute methanol:glacial acetic acid (3:1). Anal-
ysis of the karyotype was performed using G-banding of
metaphase chromosomes according to a routine procedure.
The DNA probe specific for the transgene was labeled with
biotin-dUTP by the Nick Translation Kit (Boehringer Man-
nheim) and purified on a Sephadex G-50 column. Hybrid-
ization was performed for 17 h at 37 °C. For signal
detection, cell spreads were incubated with antibodies la-
beled with fluoresceine at 37 °C. Observation of a transgene
signal was performed using a fluorescence microscope after
standard staining of cells with DABCO/PI or DABCO/
DAPI.
mRNA expression level
For RNA analysis, exfoliated mammary epithelial cells were
collected from 1 ml of milk from lactating transgenic
females by centrifugation for 5 min at 500×g at 4 °C. From
exfoliated mammary epithelial cells, total RNA was pre-
pared with the RNeasy Mini RNA kit (Qiagen). Also, tissue
biopsies (brain, heart, kidney, liver, and salivary gland) were
collected and total RNAwas isolated using the guanidinium/
isothiocyanate/phenol/chloroform extraction (Chomczynski
and Sacchi 1987). The detection of rhGH mRNA was car-
ried out by reverse transcriptase reaction using the Super-
Script®VILO™ cDNA Synthesis Kit. For PCR, 5 μl of
cDNA solution were used. PCR was performed using 35
cycles (primer annealing 62 °C; extension 72 °C; denatur-
ation 94 °C). The 173-bp cDNA fragment encompassing
part of exon 3 and exon 4 was amplified using primer
hGHcDNAF (5′-TTCATTCCTGCAGAACCCCCAG-3′) and
primer hGHcDNAR2 (5′-TGTTGGCGAAGACACTCCT-
GAG-3′). cDNA coding sequences were sequenced bi-
directionally using automated genetic analyzers (Applied Bio-
systems Prism). RNA isolated from the cells of non-transgenic
animals was used in the same analysis as a control. In search of
ectopic expression of the transgene, the studies were performed
on the brain, heart, kidney, liver, and salivary gland.
Immunoradiometric assay
Detection was performed in milk samples collected from
transgenic and non-transgenic lactating females three times
a week, once a day by turns with litter over a period of
2 weeks and stored at –80 °C until analysis. For analysis,
samples of whole milk, defatted fraction, casein fraction,
and whey fraction were separated. Eighty μl of each fraction
were taken for immunoradiometric assay (IRMA, Polatom)
analysis of rhGH concentration. Purification of growth hor-
mone was performed from 8 ml of milk (4 °C), diluted with
equal volume of phosphate buffer (50 mM phosphate buffer,
300 mM NaCl, pH 8.0). The sample was centrifuged at
2,000×g for 20 min at 4 °C. After removing a fat layer, urea
was added up to a concentration of 8 M. Two ml of immo-
bilized metal affinity chromatography resin Talon® (BD
Biosciences) were equilibrated with phosphate buffer, pH
8.0. The fat-free milk sample was then homogenized on ice
and mixed with Talon® resin. Proteins containing histidine
tag were bound to resin during 16 h of incubation with
gentle shaking at 4 °C. Unbound proteins were washed out
with phosphate buffer, pH 7.0. Proteins containing histidine
tag were eluted with phosphate buffer pH 5.0 and 4.0.
Approximately 20 μl of each sample were used for 15 %
denaturing gel electrophoresis (SDS-PAGE). For each test,
small amounts of whole milk, defatted milk, unbound pro-
teins, wash fractions, and elution fraction were used. Histidine
tag was removed by thrombin cleavage of 20-μl samples by
overnight incubation with 1 μl biotinylated thrombin, 5 μl
thrombin cleavage buffer, and water added to a final volume
of 50 μl. Following cleavage, thrombin was removed by
binding to streptavidin agarose (16 μl settled resin per unit
of enzyme). After 30 min of incubation at room temperature
with gentle shaking, agarose was removed by centrifugation at
500×g for 5 min in a spin filter. Cleavage was monitored by
gel electrophoresis of 10-μl aliquots.
Table 1 Number of
transgenic rabbits








F1 rabbits 109 32
F2 rabbits 49 34
Total 158 66
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rhGH biological activity
The rhGH biological activity assay was based on a method
described by Gout et al. (1980), with some changes (Ishikawa
et al. 2000; Schulga et al. 2002). Nb211 cells (the rat growth
hormone-dependent lymphoma cells) were grown in a com-
plete medium RPMI 1640 containing 10 % fetal calf serum
(FCS), 10 % horse serum (HS), 2 mM L-glutamine, 5 mM
HEPES buffer, pH 7.4, penicillin (50 IU/ml ), streptomycin
(50 μg/ml), and 50 μM of 2 β-mercaptoethanol in an atmo-
sphere of 5 % CO2 at 37 °C. Cell viability was assured before
each experiment by counting cells after trypan blue staining.
Twenty μl of cell suspension were sampled with 20 μl of 0.4
% trypan blue solution, incubated for 5 min. Live and dead
cells (stained blue) were counted by researchers manually
under a microscope at 10× magnification in the Bürker cham-
ber, in accordance with the two-sided principle in triplicate.
After placing a cover glass on the edges close to the grating, a
chamber was formed 0.1 mm deep, with 9 mm2 area and
9 mm3 volume. Before activity, bioassay cells were incubated
overnight in a medium as described above with 1 % fetal calf
serum instead of 10 % and without β-mercaptoethanol. The
initial number of cells was 2.5×105 live cells/ml. Two ml of
cell suspension were transferred in tissue culture dishes. Sam-
ples with different concentrations of rhGH or hGHwere added
to culture dishes in triplicate. The number of live cells was
calculated after 24, 48, and 72 h. The growth in control
cultures (without GH) was essentially zero. The proliferation
activity of recombinant human growth hormone was com-
pared with commercially available human growth hormone
expressed in HEK 293 cells (Sigma Aldrich).
Results
The founder male No. 61 transmitted the transgene to the
progeny and produced both transgenic females and males.
Premature delivery of transgenic rabbits was not observed.
All transgenic F1 animals were identified and milk samples
of lactating females collected during lactation in the first
pregnancy were analyzed for the presence of hGH. Further
crossing of F1 heterozygotes generated male (No. 002) and
female (No. 012) F2 homozygotes. Only one animal of F1
generation died after birth, but subsequent analysis showed
no presence of transgene. All other animals had normal
phenotype and showed no changes in their behavior.
PCR analysis of DNA from ear samples from transgenic
rabbits confirmed the presence of transgene of expected
size. In the initial screening, two PCR reactions were per-
formed, generating 313-bp and 524-bp DNA fragments.
PCR products combined with internal markers were frac-
tionated in polyacrylamide gel under denaturing conditions.
No change in size of PCR screening fragments was
observed in all transgenic animals of F1 generation. The
screening data of the 313-bp fragment are presented in
Fig. 1 (data for the 524-bp fragment not shown). A sequence
analysis of the whole transgene confirmed that transgene in
F1 animals was 100 % identical to a sequence of the gene
construct used for the generation of founder animal No. 61.
Newborn F2 rabbits were tested for presence of the transgene
by the same technology as that used for the screening of the F1
animals. The primary cell lines from skin fibroblasts of trans-
genic F1 and F2 rabbits were established and subjected to
classical and molecular cytogenetic analysis. We discriminated
heterozygous and homozygous animals on the basis of the FISH
mapping. Examples of the results obtained for F1 heterozygous
female rabbit (No. 08) and F2 homozygous female rabbit (No.
012) are shown in Fig. 2. The same results were observed for
other transgenic heterozygotes and homozygotes. In all rabbits
with integrated transgene confirmed by PCR screening, we
detected the transgene in the q26-27 telomere region of chro-
mosome 7 (the same location as that for founder animal No. 61).
The location of the transgene is the same as that previously
described in our paper, so we can deduce that integration was
stable and it will not be lost during cell divisions.
Recombinant human growth hormone levels were deter-
mined in the serum of males and females, and in the milk of
lactating females. Samples of serum and milk fractions were
assayed using IRMA for estimation of the human growth
hormone amount. The screening procedure for the presence
of rhGH in the milk of rabbits was established with a sensitivity
below 2 μIU/ml. Recombinant human growth hormone was
detected in total unfractionated milk samples, in casein and
whey fraction from transgenic females, but not in the serum
samples of all transgenic animals.Milk fractions fromwild type
animals were negative for the presence of rhGH. The concen-
tration of rhGH in milk samples observed for the transgenic
homozygote rabbits was between 10 and 12 μg/ml (Table 2).
rhGH levels in the milk of F1 heterozygous transgenic animals
reached 0.5 μg/ml, with 97 % present in fat-free milk (casein
fraction 53 %; whey fraction 44 %). The presence of rhGH
mRNA was demonstrated in exfoliated mammary epithelial
cells isolated from the milk during various lactation phases.
Consistent evidence for the presence of rhGH RNA in mam-
mary gland cells was obtained (Fig. 3). The transgene was not
ectopically expressed in the brain, heart, kidney, liver, and
salivary gland. All tested transgenic F1 females expressed
rhGH-mRNA in exfoliated mammary epithelial cells collected
from milk. As determined by the IRMA test, recombinant
human growth hormone was observed in late fractions collect-
ed at pH 5.0 and early fractions eluted at pH 4.0 (Fig. 4).
Fractions containing rhGHwere pooled and digested by throm-
bin to remove histidine tag. An additional step of purification
on a size exclusion column was needed to receive homogenous
rhGH band during polyacrylamide gel electrophoresis under
denaturing conditions (Fig. 4).
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The activity of rhGH was determined by an increase in
the amount of cells of the rat lymphoma line Nb211 in
response to the rhGH purified product. Hormones devoid
of lactogenic activity are not able to stimulate the prolifer-
ation of this type of cell line. The results of measurements of
proliferative activity of rhGH and commercially available
hGH after 72 h are shown in Fig. 5. The growth in control
cultures (without GH) was essentially zero (2.57×105). The
results for rhGH purified product and commercially avail-
able human growth hormone do not differ from each other,
so we can conclude that the biological activity of recombi-
nant human growth hormone produced by transgenic ani-
mals corresponds with the activity of commercially
available human growth hormone products.
Discussion
The mammary gland is considered as the best available
bioreactor. Extensive studies have shown that it can serve
as a source of a variety of complex recombinant proteins
(Houdebine 1994; Colman 1996; Clark 1998; Wall 1999;
Jost et al. 1999; Houdebine 2000). In this report, we de-
scribe transgenic rabbits carrying the WAP:6xHishGH trans-
gene with a checked expression recombinant human growth
hormone in mammary glands at the transcription and trans-
lation levels, stability of the transgene transmission, and a
mapped transgene by FISH. The normal pregnancy rates
that were observed in this study demonstrated that the gene
construct showed no interference with normal rabbit devel-
opment. The results indicate that transgene WAP:6xHishGH
became stably integrated into the host genome, can be
transmitted to the offspring, and expressed. rhGH mRNA
is specifically translated in the mammary gland and the
product secreted into the milk as biologically inactive pro-
tein. Mammary epithelial cells, which are the source of
milk-specific protein in the mammary gland, were con-
firmed to express the transgene.
There is a strong demand for recombinant growth hor-
mone and its pharmaceutical applications has expanded
during the last several years. The substantial cost limits
dramatically the utilization of growth hormone. The primary
reason for cost relates to the complexity of recombinant DNA
technology and inherited costs of this technology. One rabbit
Fig. 1 Transmission of rhGH
transgene to rabbits of F1
generation. Presence of
transgene was observed in both
female and male heterozygote
rabbits. A screening of the
transgene was performed by
polymerase chain reaction
(PCR) encompassing 313-bp
and 524-bp (not shown) DNA
fragments. PCR primers were
located upstream and down-
stream of histidine tag and
thrombin recognition site of the
gene construct. The red arrows
indicate transgene in founder
rabbit No. 61 and his F1 male
and female offspring of the
same size as the input DNA
fragment (positive control in
line 38). PCR observation was
confirmed by sequencing. The
black arrow indicates the inter-
nal marker of 268 bp. The pur-
ple arrow indicates the internal
marker of 113 bp (Color figure
online)
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female can produce up to 10 liters of milk per year. Assuming
that expected expression is about 1–10 g/l, a rabbit colony of a
few hundred animals can supply a substantial amount of hor-
mone.We are to continue experiments of further crossbreeding
the transgenic animals of the highest rhGH expression to
obtain a representative group of animals to produce large
amounts of recombinant protein. Alternative technologies to
produce replacement therapeutic proteins, including growth
hormone, are the subject of extensive research. During recent
years, the production of a variety of human proteins in trans-
genic animals has been reported, including alpha 1-antitrypsin
(Massoud et al. 1991), factor VIII (Niemann et al. 1999), anti-
thrombin, human tissue type plasminogen activator (Ebert et
al. 1991), protein C (Velander et al. 1992), interleukin 2, alpha-
galactosidase, human thrombopoietin (Sohn et al. 1999), su-
peroxide dismutase (Strömqvist et al. 1997), erythropoietin
(Massoud et al. 1996), and lactoferrin (van Berkel et al.
2002), as well as growth hormone (Devinoy et al. 1994;
Limonta et al. 1995; Dyck et al. 1999).
Generating homozygotes enabled a comparison of the ex-
pression of recombinant human growth hormone in the milk
of transgenic animals in homozygous and heterozygous ani-
mals and to study the regulation of the expression. The ex-
pression can differ between animals and during lactation in
one animal. It is an individual pattern. By crossbreeding
animals with higher rhGH production, we can obtain animals
with elevated levels of a recombinant protein. The breeding
and biology of the reproduction of rabbits is relatively easy, so
we can increase the level of production of rhGH protein by the
generation of a greater number of lactating transgenic rabbits.
a
b
Fig. 2 Mapping of a recombinant human growth hormone transgenewas
performed by fluorescence in situ hybridization (FISH) analysis using
primary culture of skin fibroblasts (heterozygous and homozygous
rabbits) and a transgenic gene construct as a molecular probe. The trans-
gene was mapped to chromosome 7 on the metaphase plates of rabbits. a
The white arrow indicates fluorescence signals observed in heterozygous
female No. 08. b The yellow arrows indicate fluorescence signals ob-
served in interphase nucleus, the red arrows the prophase, and the green
arrows the metaphase of transgenic homozygote female rabbit number
No. 012 of F2 generation (Color figure online)
Table 2 Expression of recombinant human growth hormone in the
milk of transgenic animals
Animals Concentration of rhGH (μg/ml)
Serum of control rabbits <0.0015
Serum of heterozygote rabbits <0.0015
Serum of homozygote rabbits <0.0015
Milk of control rabbits <0.0001
Milk of heterozygote rabbits 0.02–0.512




Fig. 3 RT-PCR analysis of total RNA from exfoliated epithelial cells
isolated from the milk of transgenic rabbits. Two μg of total RNAwere
subjected to reverse transcription using the primer located at the 3′ end
of the rhGH gene. PCR was performed using primers located in exons
3 and 4. PCR of the cDNA sample resulted in an expected product of
173 bp, whereas genomic DNA yielded a 265-bp fragment. Lane 1,
genomic DNA; lane 2, cDNA; lane 3, DNA size marker (λ DNA
EcoRI/XbaI)
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The integration of exogenous DNA into a single chro-
mosomal site was observed. Confirmation that transgene
was integrated into a single chromosomal site was per-
formed by direct methods. The monitoring of transgene
stability was observed through a breeding process and its
transmission between generations.
Most mechanisms of stable gene transfer require chromo-
somal integration, which allows for the stable transmission of
the transgene to all of the progeny. The mammalian genome
usually forms silent and condensed heterochromatin, so a phe-
nomenon called position effect manifests as the partial or com-
plete loss of an expression. Telomeres are composed of short
repeat sequences added onto the ends of chromosomes by
telomerase, which forms a cap that serves multiple functions,
including disguising the ends from appearing as double-strand
breaks and preventing chromosome fusion. Telomeres can in-
fluence the expression of nearby genes by the effect called the
telomere position effect (TPE) . The reversible silencing of
genes near telomeres (TPE) has been extensively studied. Initial
studies with mammalian cells failed to find evidence for TPE or
for the repression of telomeric transgenes in a human/hamster
hybrid cell line (Bayne et al. 1994). Another study found no
apparent influence of a telomere length on the expression of an
adjacent transgene in a human cell line (Sprung et al. 1996).
Later studies, however, demonstrated TPE in human cancer cell
lines by using transgenes located adjacent to telomeres, similar
to the approach used with yeast, in which endogenous subtelo-
meric genes show variable expression levels (Fourel et al. 1999).
In our case, with transgene mapped to the q26-27 telomere
region of chromosome 7q, we did not observed a negative
influence of the telomere position effect.
969 bp of the ratWAP promoter were sufficient to support a
satisfactory level of expression of rhGH located at the telo-
mere region of chromosome 7q. We assume that the fragment
ofWAP promoter used in our study included essential sequen-
ces required for directing expression exclusively to the mam-
mary gland, since ectopic expression of the rhGH gene
construct was not observed in this study, in spite of observa-
tions concerning the ectopic expression of other proteins
under theWAP promoter (Wall et al. 1995; Barash et al. 1999).
Numerous reports are available on the expression of trans-
gene in the mammary gland of transgenic rabbits (Limonta et
al. 1995), but further experiments are desired regarding this
issue. In this report, high and stable expression may reflect the
positional effect of the transgene integration and, probably,
multiple copy numbers of transgene. Transgenic rabbits gen-
erated in our studies could synthesize complex polypeptide in
the mammary gland without showing any changes in the
phenotype of secreting females and offspring, indicating that
transgenic rabbits could serve as bioreactors.
1 2
Fig. 4 Electrophoresis of purified human growth hormone in 17 %
polyacrylamide gel with SDS stained with Coomassie Blue. Electropho-
resis showed the homogeneity of growth hormone. Lane 1, recombinant
human growth hormone purified by affinity chromatography and cleaved






















Growth hormone concentration (ngx10 3/ml)
rhGH
hGH
Fig. 5 Growth hormone bioactivity assay. The effect of the biological
activity of rhGH (black line) and human growth hormone (red line)
measured by live cell numbers (cells × 105/ml) after 72 h of growing
under different growth hormone concentrations (ng × 10-3/ml) (Color
figure online)
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